Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results

12 Feb 2026 07:50 CET

Oslo, Norway, 12(th) of February 2026

Vistin Pharma ASA (VISTN) today announces the financial results for the fourth
quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a
record year for Vistin Pharma with all-time high revenue and EBITDA.

Revenue in the fourth quarter ended at MNOK 111 compared to MNOK 114 in Q4
2024. Record high sales volume in quarter (+9%), offset by lower global
metformin prices compared to same quarter last year. 2025 full year revenue
ended at all-time high MNOK 452 compared to MNOK 430 last year. Sales volume
increased by 12% in 2025.

Fourth quarter EBITDA ended at MNOK 26 compared to MNOK 28 in Q4 2024. EBITDA
was positively affected by higher sales volume, offset by product mix compared
to same quarter last year. 2025 full year all-time high EBITDA of MNOK 115
compared to MNOK 104 last year, a 10% increase

Earnings per share for 2025 ended at NOK 1,69 compared to 1,42 in 2024, an
increase of 19%.

"We are pleased with our 2025 results which shows that we are able to grow our
top- and bottom line through strong commercial execution creating healthy
earnings for our owners"
Magnus Tolleshaug, CEO

Vistin has a strong balance sheet with equity ratio of 75% and net cash position
of MNOK 16 as of year-end.

Based on preliminary 2025 results the Board of Directors will propose for the
AGM to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid
partly with NOK 1 in May and up to NOK 0.50 in November.

The fourth quarter conference call, which will be held today, 12th of February
at 8.30am (CET), will be available via webcast and audio through the following
access points:

Webcast: https://edge.media-server.com/mmc/p/fuobg9oe
(https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fedge.media-
server.com%2Fmmc%2Fp%2Ffuobg9oe&data=05%7C02%7CAlexander.Karlsen%40vistin.com%7C
b8f3f761ddbb4c48c56708de3c8a5c92%7C2fcdf060b2c2456e8bb7944b7e40981a%7C0%7C0%7C63
9014762547224258%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDA
wMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=MKU4zm5
IzoV9nfficTSyMfBSMLoR4b5FpFKCQNcKd54%3D&reserved=0)

Telephone conference (online registration):
https://register-conf.media-
server.com/register/BI64a611c39d97475c8ddf70bb07d2a9b6

The conference call will be held in English.

Please find the Q4 report and presentation enclosed. The report and webcast
(recorded) will also be made available on www.vistin.com
(http://www.vistin.com).

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

665554_Vistin Pharma_Q4_25_presentation.pdf
665554_Vistin Pharma ASA Q4 report 2025.pdf